Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma

医学 哮喘 药代动力学 药效学 人口 加药 恶化 呼出气一氧化氮 药理学 胸腺基质淋巴细胞生成素 非金属 内科学 肺活量测定 环境卫生
作者
Neang S. Ly,Yanan Zheng,Janet M. Griffiths,René van der Merwe,Balaji M. Agoram,Jane R. Parnes,Lorin K. Roskos
出处
期刊:The Journal of Clinical Pharmacology [Wiley]
卷期号:61 (7): 901-912 被引量:27
标识
DOI:10.1002/jcph.1803
摘要

Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial cytokine involved in asthma pathogenesis. In the phase 2b PATHWAY study (ClinicalTrials.gov identifier: NCT02054130), tezepelumab significantly reduced exacerbations in adults with severe, uncontrolled asthma. We used pharmacokinetic (PK) and pharmacodynamic (PD) modeling to guide tezepelumab dose selection for phase 3 trials in patients with severe asthma. PK data from 7 clinical studies were used to develop a population PK model. Population PK-PD models were developed to characterize the relationship between tezepelumab PK and asthma exacerbation rate (AER) and fractional exhaled nitric oxide (FeNO) levels (using phase 2b PD data only). Tezepelumab PK were well described by a 2-compartment model with first-order absorption; PK parameter estimates were consistent with those of other immunoglobulin G2 antibodies. PK-PD models predicted that subcutaneous dosing at 210 mg every 4 weeks was associated with ≈90% of the maximum drug effect of tezepelumab on AER and FeNO; further dose increases were not expected to result in additional, clinically meaningful treatment benefit. No clinically significant covariates of treatment effects on AER and FeNO were identified. Population PK simulations, exposure-response relationships and safety profiles of tezepelumab at doses up to 280 mg every 2 weeks suggested that no dose adjustment based on body weight or for adolescents was required. These results support the selection of 210 mg every 4 weeks subcutaneously as the dose for phase 3 studies of tezepelumab in adults and adolescents with severe asthma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小林子完成签到 ,获得积分10
1秒前
1秒前
七七完成签到,获得积分10
2秒前
jsdiohfsiodhg完成签到,获得积分10
2秒前
chenmianyuan完成签到 ,获得积分10
3秒前
4秒前
5秒前
tian完成签到,获得积分10
5秒前
cosine发布了新的文献求助10
6秒前
喜悦的绫完成签到 ,获得积分10
6秒前
7秒前
8秒前
科研小虫完成签到,获得积分10
9秒前
Lewis完成签到 ,获得积分10
9秒前
小蘑菇的应助被科研通管家采纳,获得10
10秒前
wanci的应助被科研通管家采纳,获得10
10秒前
CipherSage的应助被科研通管家采纳,获得10
10秒前
Akim的应助被科研通管家采纳,获得30
10秒前
guamo完成签到,获得积分10
10秒前
10秒前
kiluto完成签到,获得积分10
11秒前
11秒前
烟花的应助被科研通管家采纳,获得10
11秒前
CAOHOU的应助被科研通管家采纳,获得10
11秒前
星辰大海的应助被科研通管家采纳,获得10
11秒前
天天快乐的应助被科研通管家采纳,获得10
11秒前
王大橙子发布了新的文献求助10
11秒前
所所的应助被荣荣采纳,获得10
11秒前
跳跃泥猴桃完成签到,获得积分10
11秒前
所所的应助被科研通管家采纳,获得10
11秒前
领导范儿的应助被科研通管家采纳,获得10
11秒前
充电宝的应助被科研通管家采纳,获得20
11秒前
大个的应助被科研通管家采纳,获得10
12秒前
科目三的应助被科研通管家采纳,获得10
12秒前
MADAO发布了新的文献求助30
12秒前
12秒前
明亮绮菱发布了新的文献求助10
12秒前
Lucas的应助被znznznzn1234采纳,获得10
12秒前
英姑的应助被科研通管家采纳,获得10
12秒前
勤奋一一的应助被科研通管家采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571537
关于积分的说明 21818552
捐赠科研通 7778091
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479621